IT

(redirected from immunotoxin)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.

IT

The two-character ISO 3166 country code for ITALY.

IT

1. ISO 3166-1 alpha-2 code for the Italian Republic. This is the code used in international transactions to and from Italian bank accounts.

2. ISO 3166-2 geocode for Italy. This is used as an international standard for shipping to Italy. Each Italian region and province has its own code with the prefix "IT." For example, the code for the Province of Perugia is ISO 3166-2:IT-PG.
References in periodicals archive ?
sup][3],[24],[25] Other regimens, including a lymphocyte-depleting regimen, which consists of pentostatin and cyclophosphamide, were also found promising in delaying the stimulation of neutralizing anti-immunotoxin antibodies, thus allowing repetitive immunotoxin treatments for patients with solid tumors.
Immunotoxins are drugs created by linking an antibody to a portion of bacterial or plant toxin to destroy cells expressing the molecule to which the antibody binds.
Alternatively, immunotoxins (MoAbs conjugated with powerful cytotoxins such as the plant alkaloid ricin) are employed to selectively kill tumor cells.
A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vitetta and her colleagues encountered vascular leak syndrome when they began testing immunotoxins in cancer patients.
Lines with high levels of ricin could be utilized in the production of immunotoxins (Ghetie and Vitetta, 1994, Vitetta et al.
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with antitumor activity.
At the National Eye Institute in collaboration with the National Cancer Institute, an immunotoxin was developed and employed in the murine PIOL model.
GCR-3888 is an immunotoxin fusion protein between a murine anti-CD22 disulphide-linked Fv antibody fragment (dsFv) and the Pseudomonas exotoxin PE38, and GCR-8015 is an optimized version of GCR-3888 with increased affinity for CD22.
has assumed worldwide rights to develop and market LMB-9, a recombinant immunotoxin which was designed as a treatment for a wide variety of cancers.
This immunotoxin approach, using the body's immune system as a drug courier, is already under study as a cancer therapy (SN: 4/4/87, p.